Introduction
There is now much information associating desirable and undesirable actions with chemical structure and constitution and physical properties. Hundreds of thousands of natural and synthesized compounds have been subjected to bacterial, animal and human toxicological studies and the information has been stored by computer and can be retrieved as an aid to literature search when embarking on new compounds. The reason for knowing which factors are harmful is that measures can be taken to avoid them and so design safer drugs. If the relationship between structure and toxic action is known then safer drugs can be made by molecular manipulation (Aridns, 1980) . Drugs may be inherently or primarily toxic, or may increase their toxicity or become so after biotransformation. Hence the metabolic study of a drug may also result in safer therapy. The following points will be discussed-molecular structure and constitution, toxophoric groups, molecular mimicry, chemical classes, pro-drugs, molecular weight, lipid-water solubility, ionization, protein binding and isomers.
Molecular structure and constitution Some of the earliest structure-activity relationships were directed at aromatic polycyclic hydrocarbons. Some were potent carcinogens, others became so after biotransformation while others were inert. It was shown that the polycyclic hydrocarbon was usually a phenanthrene derivative with oncogenic epoxy and epoxydiol metabolites (Boyland, 1980) . Empirical correlations were made: number of rings, molecular size, shape, thickness and substituents. The carcinogenic molecule was flat or co-planar with, characteristically, areas free of substituents called bays. Strategically placed methyl groups could enhance or decrease carcinogenicity. Studies proceeded from identifying patterns, to metabolic transformation and then to the overall electron density in the molecules. Areas of special reactivity corresponding to regions of electron density were identified (e.g. K region) and the sites of epoxidation were related to electron distribution. Other carcinogenic molecules were found: aromatic amines, by virtue of N-hydroxylation and esterification; nitrosamines, by metabolism forming a reactive carbonium which alkylates natural cell polymers; nitrosamides; azo dyes; and alkylating agents (Connors, 1979; Selkirk, 1980) . Unifying concepts were sought to explain how these agents, as well as ion-radicals and free-radicals, could cause cancer. The best answer is that carcinogens are all strongly electron-deficient and hence electrophilic. They will readily attack electron-rich nucleophiles such as the bases in DNA. Carcinogenic molecules are usually mutagenic and this has proved a useful screening test (Venitt, 1980) . Electrophilic substances such as metronidazole are widely used and, while clinical experience with it is to date reassuring, careful follow-up of treated patients is advised (Goldman, 1980) .
Toxophores
The importance of knowing which part of a structure is responsible for toxicity is illustrated by the time, research and money spent on the unpredicted and inexplicable behaviour of practolol. Certain groups are unduly associated with toxicity such as the thiourea moiety which causes marrow depression. Thus metiamide was replaced by cimetidine with the less dangerous cyanoguanidine group. Nitro groups gained a bad reputation in the form of nitrobenzene; chloramphenicol is an aliphatic derivative of nitrobenzene but the mechanism of causing marrow aplasia is unknown. Nitro-imidazoles are widely used but marrow depression is not one of their effects. Another example of the value of identifying the toxophore is thalidomide. Studies showed it was the phthalimido group which reacted with DNA and accordingly chemists were able to modify its structure and produce the related taglutamide which does not appear to be teratogenic.
In other cases where metabolic studies have shown that toxic metabolites are formed the offending part of the molecule can be shielded sterically so as to prevent toxogenic metabolites. Another strategy is to introduce an alternative metabolic pathway, thus deviating metabolic conversion from a risky process to a safer attack on, for instance, an alkyl group (Arians, 1980; Ariens and Simonis, 1979) .
Antimetabolites
The introduction of sulphonamides led to the far-reaching concept of antimetabolites. Most The lead drug has the run of the market so second and third generation drugs must possess something special to succeed. One clear advantage is safety during manufacture (Ariens, 1980) as well as in the patient. Both the increase in potency and selectivity, by leading to smaller doses, possess advantages (Ariens, 1980 
Ionization
Most drugs are weak acids or bases and exist as a mixture of ionized and un-ionized species. The proportion depends on the pH of the medium and the pKa (the pH at which an acid or base is half ionized). The ionization of urinary excreted acids or bases is hence influenced by the urinary pH, and reabsorption can be enhanced or decreased with corresponding toxicity. Uncharged molecules are reabsorbed whereas ionized forms are excreted. If antacids that are absorbed are taken concurrently with an organic amine the latter's absorption will be enhanced. Sodium bicarbonate intake will increase the reabsorption of amphetamine. By the same token antacids will promote the reabsorption of quinidine, and acetazolamide, which makes the urine alkaline, will have the same effect. The pH partition theory also explains why basic drugs such as erythromycin are present in milk (Catz and Giacoia, 1972 (Stenlake, 1979) and the drugs with the greatest affinity for albumin are organic anions such as phenylbutazone and warfarin. Albumin is also quantitatively the most important binding protein for neutral molecules (Lindup and Orme. 1981) . Bases are believed to be bound to globulins and to an a1-acid glycoprotein (Lindup and Orme, 1981 (Taylor et al., 1980) .
Isomers
Isomers differ in toxicity as is the case with D and L-penicillamine. Pharmacokinetic responses may differ as well between isomers. The 2 stereoisomers of warfarin the R and S forms are dealt with metabolically in different ways: the S(-) enantiomer is 7-hydroxylated and is more potent and has a longer half-life than the R(+) isomer which is changed to warfarin alcohol. Phenylbutazone stereospecifically inhibits the metabolism of the more powerful S(-) form and this is more likely the basis for the harmful interaction than drug-protein displacement.
Bioavailability
Pharmaceutic difficulties arise from many reasons relating to solubility, dissolution, disintegration and chelation and have been extensively reviewed elsewhere; side effects are caused by differences in formulation of drugs (Groves, 1979) .
